The popularity of GLP-1 weight-loss medications continues to soarand their uptake is helping to push down obesity rates on a national scalebut a safe, evidence-based way off the drugs isnt yet in clear view
One of the most exciting future directions for GLP-1-mediated therapeutic interventions is personalized diabetes care
In this particular case, were providing additional access to beneficiaries who wouldnt otherwise be covered by Medicare for obesity indications, and so theres access to additional patients who could really benefit from these medications, and thats mutually beneficial for both the taxpayer, for those beneficiaries, as well as for the companies
Endogenous activation of glucagon-like peptide-1 receptor contributes to blood pressure control: role of proximal tubule Na(+)/H(+) exchanger isoform 3, renal angiotensin II, and insulin sensitivity
The symptoms are usually most pronounced during the first few weeks of treatment and following dose increases, generally improving as your body adapts to the medication